Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy

Journal of Clinical Laboratory Analysis

Volumn 13, Issue 6, 1999, Pages 308-311

  Wu, James T ^a,c   Wu, Tsu Lan ^b   Chang, Christine P Y ^b   Tsao, Kuo Chien ^b   Sun, Chien Feng ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c ARUP LABORATORIES   (United States)

Author keywords

Hormonal resistance; Neuroendocrine cells

Indexed keywords

CHROMOGRANIN A; FLUTAMIDE; LEUPRORELIN;

ARTICLE; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG TARGETING; HORMONE RESISTANCE; HUMAN; MALE; MALE GENITAL TRACT CANCER; NEUROSECRETORY CELL; PROSTATE CANCER; SERUM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CHROMOGRANIN A; CHROMOGRANINS; FLUTAMIDE; HUMANS; IMMUNOENZYME TECHNIQUES; LEUPROLIDE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0032698866     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1999)13:6<308::AID-JCLA10>3.0.CO;2-O     Document Type: Article

References (14)

1. Deftos LJ. Chromogranin A - its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991; 12:181-186.
2. Angelsen A, Syversen U, Haugen OA, et al. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings ? Prostate 1997;30:1-6.
3. Di Sant-Agnese P, Cockett ATK. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-361.
4. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson Jr HF, Cathepsin D. Chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80:2109-2119.
5. Kadmon D, Thompson TC, Lynch GR, Sardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;146:358-361.
6. Di Sant-Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate Suppl 1998;8:74-79.
7. Wu T-L, Chang P-Y, Tsao K-C, Sun C-F, Wu JT. Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases. J Clin Lab Anal 1999;13:312-319.
8. Kumra N, Hoshi S, Takahashi M, et al. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997;157:565-568.
9. Deftos LJ, Abrahamsson P-A. Granins and prostate cancer. Urology 1998;51(Suppl 5A):141-145.
10. Wu JT. Measurement of AFP and its lectin reactive isoforms in liver diseases and various malignancies. Ann Clin Lab Sci 1990;20:98-105.
11. Brown JA, Roberts CS. Elevated serum alpha-fetoprotein levels in primary gallbladder carcinoma without hepatic involvement. Cancer 1992;70:1838-1843.
12. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptro gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-319.
13. Raffo AJ, Periman H, Chen M-W, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
14. Aprikian AG, Cordoncardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:395-3965.